

1 **The scientific chaos phase of the Great Pandemic:**
2 **A longitudinal analysis and systematic review of the first surge of**
3 **clinical research concerning COVID-19**

4 Till Adami^{1,2*}, Markus Ries¹ (ORCID: 0000-0002-5054-5741)

5

6 ¹ Pediatric Neurology and Metabolic Medicine, Center for Pediatrics and Adolescent
7 Medicine, University Hospital Heidelberg, Heidelberg, Germany

8 ² Thoracic Oncology, Thoraxklinik Heidelberg, University Hospital Heidelberg, Heidelberg,
9 Germany

10

11 *Corresponding author

12 E-mail: till.adami@med.uni-heidelberg.de (TA)

13

14

15 **Abstract**

16 **Background**

17 Early stages of catastrophes like COVID-19 are often led by chaos and panic. To characterize the
18 initial chaos phase of clinical research in such situations, we analyzed the first surge of more than
19 1000 clinical trials about the new disease at baseline and after two years follow-up. Our 3 main
20 objectives were: (1) Assessment of spatial and temporal evolution of clinical research of COVID-19
21 across the globe, (2) Assessment of transparency and quality - trial registration, (3) Assessment of
22 research waste and redundancies.

23 **Methods**

24 By entering the keyword “COVID-19” we screened the International Clinical Trials Registry Platform
25 of the WHO and downloaded the search output when our goal of 1000 trials was reached on the 1st of
26 April. Additionally, we verified the integrity of the downloaded data from the meta registry by
27 comparing the data with each individual registration record on their source register. Also, we
28 conducted a follow-up after two years to track their progress.

29 **Results**

30 (1) The spatial evolution followed the geographical spread of the disease as expected, however, the
31 temporal development suggested that panic was the main driver for clinical research activities. (2)
32 Trial registrations and registers showed a huge lack of transparency by allowing retrospective
33 registrations and not keeping their registration records up to date. Quality of trial registration seems to
34 have improved over the last decade, yet crucial information still was missing. (3) Research waste and
35 redundancies were present as suggested by discontinuation of trials, preventable flaws in study design,
36 and similar but uncoordinated research topics operationally fragmented in isolated silo-structures.

37 **Conclusion**

38 The scientific response mechanism across the globe was intact during the chaos phase. However,
39 supervision, leadership, and accountability are urgently needed to prevent research waste, to ensure

40 effective structure, quality, and validity to ultimately break the “panic-then-forget” cycle in future
41 catastrophes.

42

43 **Introduction**

44 In December 2019 a new respiratory disease of unknown cause was detected in Wuhan City, Hubei
45 Province, China. A novel coronavirus, the severe acute respiratory syndrome coronavirus-2 (SARS-
46 CoV-2), was identified as the cause of this unexpected outbreak. Due to its vast spread and global
47 impact, the WHO declared this outbreak “a public health emergency of international concern” as early
48 as of the 30th of January 2020, more than a month prior to being officially declared a pandemic on
49 March 11, 2020.(1, 2)

50 The COVID-19 pandemic was a rapidly evolving situation, as was the scientific response: so far, the
51 WHO registered 15834 trials on their clinical trials registry platform related to COVID-19 (accessed
52 on 29th of June 2023).(3, 4) The vast amount of emerging clinical research suggested that the scientific
53 response mechanism across the globe was intact. Nevertheless, analogue to other catastrophic events
54 such as mass casualty incidents (MCI), “chaos in catastrophic events impedes decision making and
55 therefore hinders the scientific progress and thus effective treatment of patients.”(5) To surmount the
56 initial chaos phase and to create order, appropriate response process structures are needed. In the
57 scientific world of clinical research, defective process structure is often displayed by poorly designed
58 studies, information overload and redundancies resulting in unnecessary costs and effort. Insufficient
59 communication and non-transparency between researchers and institutions regarding planned,
60 ongoing, and finished research is also a hindrance.(6)

61 Trial registration is a tool which is intended to help the public and scientific world by transparently
62 displaying trial information and securing quality and validity. By minimizing publication,
63 reproducibility and selective reporting bias, the value of research and publications is meant to be
64 improved.(7)

65 In analogy to the chaos phase in the first minutes of an MCI, we examined the “scientific chaos phase”
66 of such a new pandemic situation by analyzing and reviewing the registration records of the first 1000
67 trials related to COVID-19 to detect possible flaws and opportunities for improvement in the future.

68

69 To assess lessons-learned, we developed the following 3 main objectives:

70

<i>Main objectives</i>	Questions	Instruments	Hypothesis
<i>(1) Assessment of Spatial and Temporal Evolution of Clinical Research of COVID-19 across the globe</i>	How was the geographical and temporal development of clinical research?	WHO trial registration data (date of registration, origin country), ECDC confirmed cases, UN population estimations	In the absence of a coordinating body, research follows the spread of the disease out of pragmatism, sense of urgency and panic
<i>(2) Assessment of Transparency and Quality - Trial Registration</i>	Is the data for each trial record transparent, accurate and up to date? How is the overall quality of trial registration?	Data from registration records of each trial, publication search on several platforms, WHO trial registration data set and main criteria from WHO primary registry guidelines	While it is extensively used in expert communities it is possible that there is little awareness, training, and rare usage of trial registries among a broad spectrum of health care professionals, therefore we hypothesized that there is a lack of tools for scientists to enable collaboration and communication
<i>(3) Assessment of research waste and redundancies</i>	Are there any signs of research waste and redundancies in the overall pattern of	Analysis of study design, different therapeutic agents being tested,	A surge like this is susceptible for poorly designed studies and similar study

clinical trials?	discontinuation of trials with stated reasons	objectives resulting in a waste of resources and unnecessary exposure to clinical research because of a lack of central coordination and therefore supervision
------------------	---	--

71

72

73 **Materials and methods**

74 This study was designed as a systematic review of the first 1000 clinical trial registration records
75 registered in the WHO Registry Network related to COVID-19 to depict the scientific chaos phase of
76 the pandemic. We followed the “Preferred Reporting Items for Systematic Reviews and Meta-
77 Analyses” (PRISMA) guideline for reporting this study and included the checklist (S1 Supporting
78 information). This review was not registered.

79

80 **Data sources and eligibility**

81 The World Health Organizations International Clinical Trials Registry Platform (WHO ICTRP) is a
82 registry network (“meta-registry”) which gathers registration records from primary and partner
83 registries and other data providers like ClinicalTrials.gov which meet the WHO registry criteria and
84 the WHO Trial Registry Data Set (TRDS). (8-10)

85 To analyze the first surge of clinical research and cover the “scientific chaos phase” we decided to take
86 a convenience sample of the first 1000 registered trials on the WHO ICTRP related to COVID-19. By
87 entering the keyword “COVID-19” without any filters into the search portal of the WHO ICTRP
88 (URL: <https://apps.who.int/trialsearch/>) we checked the number of registered trials on a regular basis.

89 The goal of 1000 trials was reached on the 1st of April 2020. The search output was downloaded on the
90 22nd of April 2020 at 12:57:03 CET as a CVS-file and imported into Microsoft Excel with a total of
91 1528 eligible trials. The data used in this study is publicly accessible.

92

93 **Data extraction**

94 The downloaded data set consists of the following 22 items for each trial: Trial ID, Public and
95 Scientific Title, Primary Sponsor, Date of Registration, Source Register, Recruitment Status, Inclusion
96 Age minimum and maximum, Inclusion Gender, Date of First Enrolment, Target Size, Study Type,
97 Study Design, Phase, Countries, Contact Information, Inclusion and Exclusion Criteria, (studied)
98 Health Condition, Intervention, Primary Outcome. The ICTRP also provides a hyperlink for each trial

99 which leads to the original record of the source register so users can view additional information if
100 necessary.

101 For our first objective, the spatial and temporal spread of clinical research across the globe, we
102 additionally extracted the country of origin from each original record.

103 During the follow-up and for our second objective (the assessment of transparency and quality
104 assessment of trial registration) and third objective (the assessment of redundancies and research
105 waste) we extracted the following additional information from each original record: date of last
106 update, current recruitment status, expected or actual recruitment completion date, detailed
107 information about the study design (i.e., method of allocation, masking and assignment) and detailed
108 information about the intervention (i.e., therapeutic agents being used, dosage, frequency and duration
109 of application).

110

111 **First objective: assessment of spatial and temporal evolution of** 112 **clinical research of COVID-19 across the globe**

113 To assess our first objective, we included all observational and interventional trials. We used the date
114 of registration, the country of origin and the source register of each trial. All trials were divided
115 according to their country of origin, countries with less than 10 trials were summarized as “other”. For
116 better comparability and to determine if there are differences in research activity related to the
117 population of a country or the incidence of COVID-19 cases we calculated the cumulative number of
118 trials per 1 million inhabitants as well as the cumulative number of trials per 100 confirmed cases. The
119 population of a given country was extracted from data published by the United Nations, Department of
120 Economic and Social Affairs in the “2022 Revision of World Population Prospects” (we used the most
121 recent estimation from the 1st of July 2021). The cumulative number of confirmed cases (on the 1st of
122 April 2020) per continental region was extracted from the data published by the European Centre for
123 Disease Prevention and Control (ECDC). The numbers of registered trials per 1 million inhabitants
124 and per 100 confirmed cases were calculated by dividing the total number of registered trials from
125 each continental region by the population respectively the confirmed cases of this region multiplying it

126 with 1.000.000 respectively 100. Furthermore, to assess if research followed the spread of the disease
127 due to missing coordination as we hypothesized, we graphically displayed the evolution of cumulative
128 trials per region compared to the cumulative confirmed cases in this region. Additionally, to determine
129 what impact official declarations from institutions like the WHO might have had on the research
130 activity, we divided all trials in two groups depending on whether the trial was registered before or
131 after COVID-19 was declared a pandemic. Lastly, we analyzed which registers were used most
132 frequently and from which countries.

133

134 **Follow-up assessment**

135 On the 11th of August 2022, more than 2 years after our initial data was collected, we initiated a
136 follow-up search for each interventional trial to evaluate their progress and if the trials had been
137 updated. From each original registration record, we manually extracted the latest recruitment status,
138 overall trial status and the date of the last update. In this process we also identified if the investigated
139 trials were active or discontinued. The discontinued trials were analyzed separately in our third
140 objective (Assessment of Research Waste and Redundancies) for their reason of discontinuation and
141 their investigated therapeutic agents.

142 Additionally, on the 18th of November 2022, more than 2,5 years after our initial data was collected,
143 we performed a publication search for all active interventional trials, to find peer-reviewed and
144 preprint articles. For this we used each individual Trial-ID and entered them into 4 major databases:
145 LitCovid (<https://www.ncbi.nlm.nih.gov/research/coronavirus/>) & CochraneLibrary
146 (<https://www.cochranelibrary.com> , with filter “all text”) for peer-reviewed publications and MedRxiv
147 (<https://www.medrxiv.org>) & preVIEW:COVID-19 (<https://preview.zbmed.de> , with filter “Multi”)
148 for preprint publications. Also, we verified if the publications or a summary of the results were linked
149 to each trial protocol on their respective website as demanded by the WHO. Additionally, we
150 calculated the time-to-publication in months by using the date of registration and the date on which the
151 results were published first.

152

153 **Second objective: assessment of transparency and quality – trial** 154 **registration**

155 To assess our second objective, we included all active interventional trials. The following information
156 from the original data set and from each original record by manual extraction during the follow-up
157 search was used: original and latest recruitment status, date of first enrolment, estimated or actual
158 study completion date and the date of the last update. First and foremost, we compared the original
159 recruitment status with the latest recruitment status. The original recruitment status was either labelled
160 as “not recruiting” or “recruiting” for each record. The latest recruitment status was, depending on the
161 source register, described as “not yet recruiting”, “recruiting”, “active, not recruiting”, “enrolling by
162 invitation”, “completed” and sometimes not stated at all. Analogue to the original recruitment status
163 “not yet recruiting” and “active, not recruiting” was coded as “not recruiting”, “enrolling by
164 invitation” was coded as “recruiting”. With the date of first enrolment, the estimated or actual
165 completion date and the latest recruitment status we checked if trials exceeded either their date of
166 enrolment and were still labelled as “not recruiting” or exceeded their estimated date of completion
167 and were still labelled as “recruiting” and therefore should have had been updated. In addition to the
168 publication search we checked if the published trials were labelled as “completed”. Also, we checked
169 each record for retrospective registration by comparing the date of first enrolment with the date of
170 registration. If the date of registration was in the past or on the date of first enrolment the trial was
171 coded as “prospectively registered”, otherwise it was coded as “retrospectively registered”. Lastly, by
172 comparing the date of the last update with the date of registration we checked if there were trials
173 which never had been updated.

174 To assess the quality of the trial registrations, we screened each original registration record for
175 completeness of the Trial Registration Data Set (TRDS, version 1.3.1) which currently contains 24
176 items. (9) The complete list of the 24 items including the explanation at which point an item was
177 considered as missing or displayed insufficiently is shown in (S2 Supporting information).

178

179 **Third objective: assessment of research waste and redundancies**

180 To assess our third objective, we included all interventional trials. first analyzed all discontinued trials
181 for their reason of discontinuation and the rate of discontinuation per register.

182 After that we analyzed the study design of all active interventional trials. For this analysis, the
183 following data from the original dataset was used or was manually extracted from the original record:
184 method of allocation, masking, study assignment, if a control group was present, which type of control
185 was established (standard operating procedures/standard of care vs. placebo vs. active comparator),
186 study phase and sample size.

187 Additionally, we identified all active and discontinued interventional trials which investigated
188 therapeutic agents except those which investigated complementary or alternative medicine such as
189 traditional Chinese medicine and trials which used any advanced medicinal products such as umbilical
190 cord stem cells. After that we screened those trials for each therapeutic agent being investigated to
191 determine how often each drug was tested, and which was tested most often. We divided the results
192 into active and discontinued trials to determine how many trials originally planned on investigating
193 those interventions.

194

195 **Statistical analysis**

196 We used standard methods for descriptive statistics. All variables are either expressed as mean values
197 with standard deviation, medians, and ranges or with absolute counts and percentages. Figs 4-5 are
198 displayed as box-whiskers-plots. Temporal analyzations are displayed in months. Data analysis and
199 figures were performed using SPSS (version 29, IBM) and Microsoft Excel.

200

201 **Results**

202 **Trial selection**

203 The trial selection is displayed in a flow diagram according to the PRISMA-guidelines. (Fig 1) On the
204 1st of April our targeted convenience sample size of 1000 studies was exceeded. To avoid any sort of
205 bias by falsely excluding any trials - since we could not identify which trial was the 1000th - we

206 included all trials registered until that day, resulting in a total of 1017 eligible trials. After excluding
207 trials not related to COVID-19, duplicates and trials withdrawn from the registry we ended up with
208 991 included trials. For our first objective we included all 991 trials. As the ICMJE and WHO
209 consider trial registration to be mandatory only for interventional trials, we included only
210 interventional trials for our follow-up search, our second objective (Assessment of Transparency and
211 Quality Assessment – Trial Registration) and our third objective (Assessment of Redundancies and
212 Research Waste) (n = 593). As we examined the trial registration process itself with these objectives,
213 inclusion of observational trials would have led to false alteration of results as every information given
214 about their trial registration can be considered voluntary. (7) During the follow-up we identified 103
215 discontinued interventional trials which will be analyzed separately in our third objective for their
216 reason of discontinuation and their investigated therapeutic agents. Therefore, for our second objective
217 (assessment of transparency and quality) we included all 490 active interventional trials and for our
218 third objective (assessment of research waste and redundancies) we included all 593 interventional
219 trials.

220

221 **Fig 1. PRISMA-flow chart of trial selection: eligibility and inclusion process for each objective**

222

223 **First objective: assessment of spatial and temporal evolution of** 224 **clinical research of COVID-19 across the globe**

225 The very first trial related to COVID-19 was registered on the 23rd of January. While there were only
226 15 trials registered in the last week of January, the numbers rapidly increased to 360 registered trials in
227 February, rising to 568 trial registrations in March and 48 registrations only on the 1st of April,
228 resulting in a total of 991 registered trials in less than 3 months. The first trials had their origins in
229 China while the first trial outside of China was registered on the 5th of February 2020 in France. For a
230 clearer demonstration of the differences in trial emergence, we graphically displayed the temporal
231 evolution of trial registration in China compared to the rest of the World. (Fig 2)

232

233 **Fig 2. Evolution of trial registrations in China vs. rest of the world**

234 X-axis: Timeline from 23rd January 2020 to 01st April 2020, Y-axis: Cumulative trials registered in the
 235 ICTRP with the keyword COVID-19 from China (blue) and the Rest of the World (orange). Data was
 236 extracted from the original dataset downloaded from the ICTRP and from the original registration
 237 record of each trial.

238
 239 All in all, we identified a total of 39 different countries with 11 countries registering 10 or more trials.
 240 All countries with less than 10 trials will be summarized as “other”. China had by far the most
 241 registered trials with a total of 663 (66,9 %) of all 991 trials. Second most often was USA with 61
 242 (6,2 %) followed by France with 44 (4,4 %), Iran with 40 (4,0 %) and Italy with 24 (2,4) trials. The
 243 remaining 159 trials originated in decreasing numbers from Germany, United Kingdom, Netherlands,
 244 Spain, Canada, Japan, and others. If calculated by trials per 1 million inhabitants, Netherlands (0,80),
 245 France (0,682) and China (0,465) were leading. Considering the number of trials per 100 confirmed
 246 cases China led with 0,806 trials per 100 cases, followed by Japan with 0,512 and Canada with 0,141.
 247 (Table 1)

248 **Table 1. Spatial and temporal analysis of all 991 observational and interventional trials**

	CHN	USA	FRA	IRN	ITA	DEU
Registered trials in numbers n						
Total	663 (66,9 %)	61 (6,2 %)	44 (4,4 %)	40 (4,0 %)	24 (2,4 %)	19 (1,9%)
January	15 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
February	349 (96,9%)	6 (1,7%)	2 (0,6%)	0 (0%)	0 (0%)	0 (0%)
March	293 (51,6%)	51 (9,0%)	36 (6,3%)	34 (6,0%)	24 (4,2%)	15 (2,6%)
1st of April	6 (12,5%)	4 (8,3%)	6 (12,5%)	6 (12,5%)	0 (0%)	4 (8,3%)
Before declaration	461 (69,5%)	9 (14,8%)	5 (11,4%)	0 (0%)	0 (0%)	0 (0%)
After declaration	202 (30,5%)	52 (85,2%)	39 (88,6%)	40 (100%)	24 (100%)	19 (100%)
Per 1 million inhabitants	0,465	0,181	0,682	0,455	0,405	0,228
Per 100 confirmed cases	0,806	0,032	0,084	0,09	0,023	0,028
Trials per register in numbers n						
ChiCTR	560 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
ClinicalTrials.gov	103 (31,7%)	61 (18,8%)	31 (9,5%)	3 (0,9%)	24 (7,4%)	8 (2,5%)
IRCT	0 (0%)	0 (0%)	0 (0%)	37 (100%)	0 (0%)	0 (0%)

	EU-CTR	0 (0%)	0 (0%)	11 (42,3%)	0 (0%)	0 (0%)	2 (7,7%)
	JPRN	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	Other	0 (0%)	0 (0%)	2 (6,1%)	0 (0%)	0 (0%)	9 (27,3%)
	Total	663 (66,9%)	61 (6,2%)	44 (4,4%)	40 (4,0%)	24 (2,4%)	19 (1,9%)

249 CHN, China; USA, United States of America; FRA, France; IRN, Iran; ITA, Italy; DEU, Germany;
 250 GBR, Great Britain; NLD, Netherlands; ESP, Spain; CAN, Canada; JPN, Japan. ChiCTR, Chinese
 251 Clinical Trials Registry; IRCT, Iranian Registry for Clinical Trials; EU-CTR, European Clinical Trials
 252 Registry; JPRN, Japan Primary Registry Network. All numbers are total counts. Percentages of the
 253 rows “Before declaration” and “After declaration” refer to the respective value of row “Total”.
 254 Percentages of the column “World” refer to the total 991 trials of the first row. The other percentages
 255 of each row refer to the respective value of the column “World”. Data was extracted from the original
 256 dataset downloaded from the ICTRP and from the original registration record of each trial.

257
 258 If divided into before and after COVID-19 was declared a pandemic on the 11th of March 2020, we see
 259 that the distribution is nearly even with 485 (48,9 %) registered before and 506 (51,1 %) trials
 260 registered after the declaration. A majority of 461 (95,1 %) of all 485 trials registered before the
 261 pandemic declaration originated from China while after the declaration only 201 (39,7 %) of all 506
 262 trials registered after the declaration originated from China. This is followed by the USA with 9
 263 (1,9 %) trials before and 52 (10,2 %) trials after the declaration, France with 5 (1,0 %), respectively 39
 264 (7,7 %) trials and Iran with all 40 trials (7,9%) registered after the pandemic declaration. Moreover,
 265 most of the trials originating from China were registered before the declaration with 69,6 %, while
 266 most of the trials from other regions were registered after the declaration with the U.S. registering
 267 85,2%, France registering 88,6% and Iran registering 100 % of their trials after the declaration. In
 268 addition, we graphically depicted the temporal evolution of confirmed cases compared to registered
 269 trials. In this view, it appears that the Chinese curve is already in stagnation for both cases and trials,
 270 whereas the curve of the other countries just start to rise. (Fig 3-13, Table 1)

271

272 **Fig 3-13. Cumulative trials vs. cumulative cases per country over time**

273 (Fig 3) China, (Fig 4) United States, (Fig 5) France, (Fig 6) Iran, (Fig 7) Italy, (Fig 8) Germany, (Fig
274 9) United Kingdom, (Fig 10) Netherlands, (Fig 11) Spain, (Fig 12) Canada, (Fig 13) Japan. X-Axis:
275 Timeline from the 31st of December 2019 to 01st of April 2020. Y-Axis: Logarithmic representation of
276 the cumulative number of confirmed cases of COVID-19 (blue) compared to the cumulative number
277 of registered trials regarding COVID-19 (orange) for each country. The numbers of trials were
278 extracted from the ICTRP with the keyword COVID-19, the number of confirmed cases were
279 extracted from publicly available data from European Center for Disease Control.

280
281 Overall, 12 different registries were used for registration: Chinese Trials Registry (CTR),
282 ClinicalTrials.gov, Iranian Registry of Clinical Trials (IRCT), European Clinical Trials Registry (EU-
283 CTR), Japan Primary Registry Network (JPRN), German Clinical Trials Registry (DRKS),
284 Netherlands Trial Registry (NTR), International Standard Registered Clinical Trial Number registry
285 (ISRCTN), Thailand Clinical Trials Registry (TCTR), Clinical Trials Registry India (CTRI),
286 Australian and New Zealand Clinical Trials Registry (ANZCTR) and the Brazilian Registry of
287 Clinical Trials (ReBEC). ChiCTR was used most frequently with 560 (56,5%) trials of which all
288 originated from China. Clinicaltrials.gov was used second most often with a total of 325 (32,8 %)
289 trials of which 103 originated from China, 61 from the US, 31 from France, 24 from Italy and the
290 remaining 109 trials in decreasing numbers from Canada, UK, Spain, Germany, Iran, Netherlands, and
291 others. IRCT is third with 37 (3,7 %) trials, which all originated from Iran, followed by EU-CTR with
292 26 (2,6 %) registrations and JPRN with 10 (1,0 %) registered trials. The remaining 33 trials are spread
293 over the remaining registers with all having less than 10 registrations each and therefore are
294 summarized as “other”. (Table 1)

295

296 **Follow-up assessment after 2 years**

297 For the assessment of transparency in trial registration of our second objective we conducted a follow
298 up search for all 593 interventional trials after more than two years during which we extracted the
299 latest recruitment status, overall trial status and the date of the last update. Nearly half of those trials
300 were registered with the ChiCTR (49,4 %), more than a third were registered with ClinicalTrials.gov

301 (37,1%), and the remaining were registered in decreasing order with the IRCT, the EU-CTR and the
 302 JPRN. Registers with less than 10 registrations each were summarized as “other”. During the follow-
 303 up process we identified 103 (17,4%) of those trials were discontinued. The discontinued trials were
 304 separately analyzed in our third objective for their reason of discontinuation and their investigated
 305 therapeutic agents. (Table 2)

306

307 **Table 2. Intervention trials per register and discontinuation of trials.**

	Source Register				
	ChiCTR	ClinicalTrials.gov	IRCT	EU-CTR	Other ¹
Interventional trials					
in numbers n					
Total registered interventional trials	293	220	37	26	17
Total discontinued interventional trials	39	48	0	13	3
Total active interventional trials	254	172	37	13	14
Discontinuation rate per register	13,30%	21,80%	0,00%	50,00%	17,60%
Reason for discontinuation					
in numbers n					
Not stated	33 (84,6%)	0 (0%)	-	6 (46,2%)	2 (66,7%)
Difficulties with enrolment	5 (12,8%)	22 (35,8%)	-	3 (23,1%)	0 (0%)
New evidence/treatment guidelines	0 (0%)	10 (20,8%)	-	2 (15,4%)	1 (33,3%)
Authority decision or recommendation	0 (0%)	5 (10,4%)	-	0 (0%)	0 (0%)
Changed to expanded access study	0 (0%)	5 (10,4%)	-	0 (0%)	0 (0%)
Logistics, staff, or resource issues	0 (0%)	2 (4,2%)	-	1 (7,7%)	0 (0%)
Change of study design/protocol	1 (2,6%)	2 (4,2%)	-	1 (7,7%)	0 (0%)
Planned termination criteria	0 (0%)	1 (2,1%)	-	0 (0%)	0 (0%)
Futility	0 (0%)	1 (2,1%)	-	0 (0%)	0 (0%)

308 ChiCTR, Chinese Clinical Trials Registry; IRCT, Iranian Registry for Clinical Trials; EU-CTR,
 309 European Clinical Trials Registry. All numbers are total counts. Percentages for the section “Reason
 310 for discontinuation” refer to the respective value of the row “Total discontinued interventional trials”.
 311 Data was extracted from the original dataset downloaded from the ICTRP and from the original
 312 registration record of each trial.

313 ¹Other registers include: JPRN, Japanese Primary Registry Network (n = 6); NTR, Netherlands Trial
 314 Registry (n = 3); ISRCTN, International Standard Registered Clinical Trial Number registry (n = 3);
 315 DRKS, German Clinical Trials Registry (n = 1); TCTR, Thailand Clinical Trials Registry (n = 1);
 316 ReBEC, Brazilian Registry of Clinical Trials (n = 1); ANZCTR, Australian and New Zealand Clinical
 317 Trials Registry (n = 1); CTRI, Clinical Trials Registry India (n = 1).

318

319 **Publication pattern**

320 To assess the publication pattern of the 490 active interventional trials we conducted a publication
 321 search two and a half years after our initial data was collected. We identified a total of 139 trials
 322 (28,4%) which already published results after 2 years. 84,2 % of those publications were already peer-
 323 reviewed and 15,8 % were only available as preprint articles. Of those 139 trials only 18,7 %
 324 registration records provided a link or a summary of those results on their original record on their
 325 respective source register. 3 (2,2%) trials have submitted a summary of their results to their registry,
 326 but those have not yet been published. Detailed results are shown in Table 3.

327

328 **Table 3. Publication pattern per register**

	ChiCTR	ClinicalTrials.gov	IRCT	EU-CTR	Other¹
Total active interventional trials	254 (51,8%)	172 (35,1%)	37 (7,6%)	13 (2,7%)	14 (2,9%)
Published Trials					
Total	47 (18,5%)	74 (43,0%)	6 (16,2%)	6 (46,2%)	6 (42,9%)
Peer-Reviewed	31 (66,0%)	69 (93,2%)	5 (83,3%)	6 (100%)	6 (100%)
Preprint	16 (34,0%)	5 (6,8%)	1 (16,7%)	0	0

329 ChiCTR, Chinese Clinical Trials Registry; IRCT, Iranian Registry for Clinical Trials; EU-CTR,
 330 European Clinical Trials Registry. All numbers are total counts. Percentages of the row “Total active
 331 interventional trials” refer to the total number of active trials (n = 490). Percentages of the row “Total”
 332 refer to the respective value of the row “Total active interventional trials”. Percentages of the rows
 333 “Peer-reviewed” and “Preprint” refer to the respective value of row “Total”. Data was extracted from
 334 the original dataset downloaded from the ICTRP and from the original registration record of each trial.

335 ¹Other registers include: JPRN, Japanese Primary Registry Network (n = 5); NTR, Netherlands Trial
336 Registry (n = 2); ISRCTN, International Standard Registered Clinical Trial Number registry (n = 3);
337 DRKS, German Clinical Trials Registry (n = 1); ReBEC, Brazilian Registry of Clinical Trials (n = 1);
338 ANZCTR, Australian and New Zealand Clinical Trials Registry (n = 1); CTRI, Clinical Trials
339 Registry India (n = 1).

340
341 Additionally, we graphically displayed the time to publication calculated from the date of registration
342 to the date the publications were first published. Peer-reviewed articles were published after a mean
343 time of 11,69 months (SD: 7,78), a median time of 10,59 months, the 25 percentile was 4,66 months
344 and the 75 percentile was 17,59 months. Preprint articles were published after a mean time of 4,12
345 months (SD: 2,53), a median time of 3,89 months, the 25 percentile was 2,1 months and the 75
346 percentile was 6,2 months. (Fig 14)

347
348 **Fig 14. Box-Whiskers-Plot of the time-to-publication divided into peer-reviewed and preprint**
349 **articles.**

350 X-axis: Type of publication divided into peer-reviewed and preprint articles, Y-axis: Time to
351 publication expressed in months calculated as the period from the date of registration to the date of
352 first publication. The publication search was conducted by entering each individual trial-ID into 4
353 major databases: LitCOVID, CochraneLibrary, MedRxiv and preVIEW:COVID-19. The date of
354 registration was extracted from the original database.

355
356 **Second objective: assessment of transparency and quality – trial**
357 **registration**

358 As stated above, the WHO and ICMJE consider trial registration to be mandatory only for
359 interventional trials, therefore we excluded all observational trials (n=398) for this objective, the
360 assessment of the trial registration itself.

361

362 **Assessment of transparency**

363 To assess the transparency of trial registration we excluded all trials which were found as discontinued
 364 in the follow-up search (n=103). The discontinued trials were analyzed separately for their reason of
 365 discontinuation and their therapeutic agents in the third objective. This resulted in 490 included trials
 366 and only 4 registers with more than 10 registrations: ChiCTR (n = 254), ClinicalTrials.gov (n = 172),
 367 IRCT (n = 37) and EU-CTR (n = 13). The rest of 14 trials will be summarized as others. The results
 368 for this assessment are displayed in Table 4.

370 **Table 4. Assessment of Transparency – Analysis of the Progress of Active Interventional Trials**

	Source Register			
	ChiCTR	ClinicalTrials.gov	IRCT	EU
Total active interventional trials	254 (51,8)	172 (35,1 %)	37 (7,6 %)	13 (3,1 %)
Prospective/Retrospective registration				
Prospective	135 (53,1 %)	132 (76,7 %)	13 (35,1%)	12 (30,8 %)
Retrospective	119 (46,9 %)	40 (23,3 %)	24 (64,9%)	1 (2,6 %)
Original recruitment status (time of registration)				
Recruiting	145 (57,1 %)	91 (52,9 %)	23 (62,2%)	1 (2,6 %)
Not Recruiting	109 (42,1 %)	81 (47,1 %)	14 (37,8%)	12 (30,8 %)
Latest recruitment status (11 August 2022)				
Recruiting	144 (56,7 %)	46 (26,7 %)	0 (0%)	0 (0 %)
Not Recruiting	103 (40,6 %)	44 (25,6 %)	1 (2,7%)	0 (0 %)
Completed	7 (2,7 %)	82 (47,7 %)	36 (97,3%)	6 (15,4 %)
Not Stated	0 (0 %)	0 (0 %)	0 (0%)	7 (17,7 %)
Trials exceeding enrolment date per recruitment status				
Recruiting	144 (56,7 %)	46 (26,7 %)	0 (0%)	0 (0 %)
Not Recruiting	103 (40,6 %)	44 (25,6 %)	1 (2,7%)	0 (0 %)
Completed	7 (2,7 %)	82 (47,7 %)	36 (97,3%)	6 (15,4 %)
Not Stated	0 (0 %)	0 (0 %)	0 (0%)	7 (17,7 %)
Total	254	172	37	13
Trials exceeding estimated/actual completion date per recruitment status				
Recruiting	139 (54,7 %)	38 (22,1 %)	0 (0%)	0 (0 %)
Not Recruiting	100 (39,4 %)	32 (18,6 %)	1 (2,7%)	0 (0 %)

Completed	7 (2,8 %)	81 (47,1 %)	36 (97,3%)	6 (4)
Total	246 (96,9 %)	151 (87,8 %)	37 (100%)	6 (4)
Update history of trials				
Never Updated	102 (40,2 %)	0 (0 %)	16 (43,2%)	
Within first week	69 (27,2 %)	13 (7,6 %)	5 (13,5%)	
Within first month	56 (22,0 %)	28 (16,3 %)	5 (13,5%)	
Within first half year	22 (8,7 %)	40 (23,3 %)	8 (21,6%)	
More than a half year after registration	5 (1,9 %)	91 (52,9 %)	3 (8,1%)	
Never updated trials per recruitment status				
Recruiting	54 (53,0 %)	0 (0 %)	0 (0%)	
Not recruiting	47 (46,1 %)	0 (0 %)	1 (6,3%)	
Completed	1 (0,9 %)	0 (0 %)	15 (93,8%)	
Published trials per recruitment status				
Total	47 (18,5 %)	74 (43,0 %)	6 (16,2%)	6 (4)
Recruiting	30 (63,8 %)	9 (12,2 %)	0 (0%)	0 (0)
Not recruiting	15 (31,9 %)	12 (16,2 %)	0 (0%)	0 (0)
Completed	2 (4,3 %)	53 (71,6 %)	6 (100%)	2 (3)
Not stated	0 (0 %)	0 (0 %)	0 (0%)	4 (6)
Linked to record	0 (0 %)	20 (27,0 %)	0 (0%)	2 (3)
Not Linked to record	47 (100,0 %)	52 (70,3 %)	6 (100,0%)	3 (5)
Submitted to record	0 (0 %)	2 (2,7 %)	0 (0%)	1 (1)

371 ChiCTR, Chinese Clinical Trials Registry; IRCT, Iranian Registry for Clinical Trials; EU-CTR,
372 European Clinical Trials Registry. All numbers are total counts. Percentages of the row “Total active
373 interventional trials” refer to the total number of active trials (n = 490). Percentages in the section
374 “Published trials per recruitment status” refer to the respective value of the row “Total” of the same
375 section. All other percentages refer to the respective value of the row “Total active interventional
376 trials”. Data was extracted from the original dataset downloaded from the ICTRP and from the original
377 registration record of each trial.

378 ¹Other registers include: JPRN, Japanese Primary Registry Network (n = 5); NTR, Netherlands Trial
379 Registry (n = 2); ISRCTN, International Standard Registered Clinical Trial Number registry (n = 3);
380 DRKS, German Clinical Trials Registry (n = 1); ReBEC, Brazilian Registry of Clinical Trials (n = 1);
381 ANZCTR, Australian and New Zealand Clinical Trials Registry (n = 1); CTRI, Clinical Trials
382 Registry India (n = 1).

383 *Trial records registered with the EU-CTR did not state the date of their last update, therefore no
384 calculation was possible.

385

386 First, we checked all included trials for prospective or retrospective registration and found out that
387 more than a third were registered retrospectively (37,2 %). The highest rate of retrospectively
388 registered trials had the IRCT with almost two thirds (64,9 %), followed by the ChiCTR with almost
389 half their trials being registered retrospectively (46,9 %).

390 Then we checked each trial for their original recruitment status to compare it with the findings of our
391 follow-up search after two years. Originally, more than half of the trials were registered as “recruiting”
392 (55,1 %) while the rest were registered as “not recruiting”. As of the 11th of August 2022, the date of
393 our follow-up search more than a third were still labelled as “recruiting” (39,2 %), while slightly less
394 than a third were either labelled as “not recruiting” (30,6 %) or were already labelled as “completed”
395 (28,8 %). The rest had not stated their recruitment status (1,4 %). All 490 trials exceeded their date of
396 first enrolment, which means all trials currently labelled as “not recruiting” had not been updated
397 accordingly. 91,4 % of the trials also exceeded their estimated or actual completion date of which
398 more than a third (36,1 %) were still labelled as “recruiting”. Those trials therefore had not been
399 updated accordingly as well. This adds up to a total of 66,7 % trials which had not been updated
400 accordingly.

401 Furthermore, we found out that nearly a quarter had not been updated once since their date of
402 registration (24,3 %). Out of those trials, 12,6 % were labelled as “completed” in their latest version of
403 their registration record, which implies that they were already registered as “completed” even though
404 the downloaded database from the WHO stated otherwise.

405 Additionally, we found out that slightly less than half the trials which already published results were
406 labelled as “completed” (48,9 %) with the rest either been labelled as “recruiting”, “not recruiting” or
407 not having stated any status in decreasing order.

408

409 **Assessment of quality**

410 To assess the quality of the registration records and the registries itself we checked each record for
 411 completeness of the Trial Registration Data Set (TRDS). (S2 Supporting information, Table 5) Across
 412 all registers item 13 (interventions) was most frequent with 43,9 % of all trials displaying insufficient
 413 information. Most of those trials have not stated any or insufficient information about the dosage,
 414 frequency of application or duration of the treatment. The EU-CTR had the highest rate of missing
 415 information on this item with 69,2 % of their trials, followed by the ChiCTR, the IRCT and
 416 ClinicalTrials.gov. Item 21 (ethics review) was missing second most often with 40,2 % of all trials not
 417 displaying any information on their ethics review. ClinicalTrials.gov had the highest rate of missing
 418 information on this item with 97,1 % of their records. By not stating the allocation method, masking or
 419 the type of assignment, item 15 (study type) was missing third most often in 22,4 % of all trial records.
 420 On this item the ChiCTR had the highest rate of missing information with 40,9 % of their records. The
 421 summarization of results (item 23) was missing for 79,1 % of the 139 trials which already published
 422 results by not providing a summary of the results or a link to the published results in their original
 423 record. ChiCTR and ICRT both had the highest rate of issues on this item with 100 % of their
 424 published trials not providing a summary or a link to the publication on their record. This was
 425 followed by ClinicalTrials.gov with 70,3 % and the EU-CTR with 50,0 % of their trials. The contact
 426 information for public and scientific queries (items 7 and 8) were completely missing in 3,9 % across
 427 all registers, however for another 15,9 % of all trials, the information was only available in the WHO
 428 dataset and not in the original record from the source register. Seventy-seven of these trials were
 429 registered with ClinicalTrials.gov with a rate of 44,7 % of their total 172 registered trials.

430

431 **Table 5. Assessment of quality – Completeness of the Trial Registration Data Set**

Missing TRDS Items	Number of trials with missing or insufficient information			
	ChiCTR	ClinicalTrials.gov	IRCT	EU-CTR
Total trials	254	172	37	13
4. Source(s) of monetary/material support	2 (0,8%)	0 (0%)	0 (0%)	1 (7,7%)
5. Primary Sponsor	0 (0%)	0 (0%)	0 (0%)	0 (0%)
7. Contact for public queries				
Completely missing	0 (0%)	19 (11,0%)	0 (0%)	0 (0%)

Not shown on registry website	0 (0%)	77 (44,8%)	0 (0%)	1 (7,7%)
8. Contact for scientific queries				
Missing	0 (0%)	19 (11,0%)	0 (0%)	0 (0%)
Not shown on registry website	0 (0%)	77 (44,8%)	0 (0%)	1 (7,7%)
11. Countries of recruitment	0 (0%)	13 (7,6%)	0 (0%)	1 (7,7%)
13. Interventions	155 (61,0%)	34 (19,8%)	15 (40,5%)	9 (69,2%)
Intervention name described insufficiently	42 (16,5%)	0 (0%)	0 (0%)	1 (7,7%)
Dosage, frequency, or duration missing	76 (29,9%)	4 (2,3%)	1 (2,7%)	8 (61,5%)
Standard of care as comparator	37 (14,6%)	30 (17,4%)	14 (37,8%)	0 (0%)
15. Study type	104 (40,9%)	2 (1,2%)	0 (0%)	1 (7,7%)
16. Date of first enrolment	0 (0%)	0 (0%)	0 (0%)	13 (100%)
18. Recruitment status	0 (0%)	0 (0%)	0 (0%)	12 (92,3%)
21. Ethics review	27 (10,6%)	167 (97,1%)	0 (0%)	0 (0%)
22. Completion date	1 (0,4%)	0 (0%)	0 (0%)	0 (0%)
23. Summary results	*	*	*	*
24. IPD sharing statement	8 (3,1%)	37 (21,5%)	0 (0%)	12 (92,3%)

432 ChiCTR, Chinese Clinical Trials Registry; IRCT, Iranian Registry for Clinical Trials; EU-CTR,
433 European Clinical Trials Registry. Only items which are missing information are displayed, all items
434 not mentioned have not been missing information. All numbers are total counts. All percentages refer
435 to the respective value of the row “Total trials”. Data was extracted from the original registration
436 records of each trial and analyzed according to S2 Supporting information.

437 ¹Other registers include: JPRN, Japanese Primary Registry Network (n = 5); NTR, Netherlands Trial
438 Registry (n = 2); ISRCTN, International Standard Registered Clinical Trial Number registry (n = 3);
439 DRKS, German Clinical Trials Registry (n = 1); ReBEC, Brazilian Registry of Clinical Trials (n = 1);
440 ANZCTR, Australian and New Zealand Clinical Trials Registry (n = 1); CTRI, Clinical Trials
441 Registry India (n = 1).

442 *Item 23 is represented in Table 4 in the section “Published trials per recruitment status”.

443

444 **Third objective: assessment of research waste and redundancies**

445 **Assessment of research waste**

446 For the assessment of research waste, we first investigated the discontinued trials for their reason of
447 discontinuation. During the two-year follow-up process we identified that 17,4 % of the interventional

448 trials were discontinued due to several reasons. We sorted all stated reasons for discontinuation into 8
 449 different categories. We also divided those trials by their source register and calculated the
 450 discontinued trials per total trials per register by dividing the total number of discontinued trials by the
 451 total number of trials from one register. 39,8 % of the discontinued trials unfortunately did not state
 452 any reason. After that, the most frequent reason was “difficulties with enrolment” with 29,1 % trials
 453 followed by “new evidence or new treatment guidelines” from other trials and/or publications with
 454 12,6 % trials. Divided into registers, ClinicalTrials.gov had the most discontinued trials with 56,3 % of
 455 all discontinued trials followed by ChiCTR with 37,9 % trials and EU-CTR with 12,6 %. If we look at
 456 the rate of discontinued trials per total trials per register however, we see that out of all registers with
 457 more than 10 registered trials, the EU-CTR has the highest rate of discontinued trials with 50,0 %
 458 followed by ClinicalTrials.gov with 21,8 % and ChiCTR with 13,3 %. (Table 2)

459 We further evaluated potential research waste by analyzing the study design across the remaining 490
 460 active interventional trials with extensive results shown in Table 6. Overall, randomized-controlled
 461 trials (RCT) were most common with more than two thirds of all 490 interventional trials (68,3 %),
 462 followed by single arm trials and non-randomized-controlled trials (NRCT). In the group of RCTs,
 463 44,4 % trials were not masked while 27,5 % had not given any information about their masking.
 464 Seventy-eight-point-five percent of the RCTs used “standard of care” as the control while the rest used
 465 a placebo. In the group of NRCTs 35,4 % trials were not masked and 10,4 % did not state any
 466 information on their masking. Ninety-five-point-eight percent used “standard of care” and 4,2 % trials
 467 a placebo as their control group. The most frequent study phase over all interventional trials was phase
 468 0 with 23,3 % followed by phase 2 trials with 17,3 %. The study phase of 24,9 % trials was either not
 469 applicable or not stated. The mean target size over all 490 trials was 591,56 subjects (SD 3445,83), the
 470 median 100 subjects, the 25 percentile 60 subjects and the 75 percentile 255,75 subjects. The target
 471 sizes according to each study phase are shown in Fig 15.

472

473 **Table 6. Assessment of Research Waste – Analysis of Study Design of active interventional trials.**

	Study design					
	RCT	NRCT	Single Arm	RP	Sequential	N
Total	335 (68,4%)	48 (9,8%)	61 (12,4%)	20 (4,1%)	14 (2,9%)	8 ()

Masking						
None	149 (44,5%)	17 (35,4%)	47 (77,0%)	11 (55,0%)	2 (14,3%)	5 (6)
Single	26 (7,8%)	0 (0%)	0 (0%)	5 (25,0%)	0 (0%)	0 (0)
Double	36 (10,7%)	2 (4,2%)	0 (0%)	0 (0%)	0 (0%)	0 (0)
Triple	7 (2,1%)	0 (0%)	0 (0%)	1 (5,0%)	0 (0%)	0 (0)
Quadruple	25 (7,5%)	0 (0%)	0 (0%)	1 (5,0%)	0 (0%)	0 (0)
N/A	6 (1,8%)	24 (50,0%)	13 (21,3%)	0 (0%)	14 (100%)	3 (3)
Not Stated	86 (25,7%)	5 (10,4%)	1 (1,6%)	1 (5,0%)	0 (0%)	0 (0)
Control						
None	0 (0%)	0 (0%)	61 (100%)	20 (100%)	13 (92,9%)	7 (8)
Standard of Care	263 (78,5%)	46 (95,8%)	0 (0%)	0 (0%)	1 (7,1%)	1 (1)
Placebo	72 (21,5%)	2 (4,2%)	0 (0%)	0 (0%)	0 (0%)	0 (0)
Study Phase						
0	77 (23,0%)	14 (29,2%)	12 (19,7%)	1 (5,0%)	6 (42,9%)	1 (1)
1	13 (3,9%)	3 (6,3%)	12 (19,7%)	2 (10,0%)	2 (14,3%)	1 (1)
2	59 (17,6%)	9 (18,8%)	12 (19,7%)	3 (15,0%)	0 (0%)	2 (2)
3	52 (15,5%)	2 (4,2%)	4 (6,6%)	7 (35,0%)	0 (0%)	1 (1)
4	55 (16,4%)	7 (14,6%)	2 (3,3%)	4 (20,0%)	1 (7,1%)	1 (1)
N/A	79 (23,6%)	13 (27,1%)	19 (31,1%)	3 (15,0%)	5 (35,7%)	2 (2)

474 RCT, Randomized Controlled Trial; NRCT, Non-Randomized Controlled Trial; RP, Randomized
475 Parallel Trial; NRP, Non-Randomized Parallel Trial. All numbers are total counts. Percentages of the
476 row “Total” refer to the total number of active interventional trials (n = 490). All other percentages
477 refer to the respective value of the row “Total”. Data was extracted from the original dataset
478 downloaded from the ICTRP and from the original registration record of each trial.

479

480 **Fig 15. Box-Whiskers-Plot of the Target Sizes per Study Phase of all active interventional trials**

481 X-axis: Active interventional trials separated into the different study phases; N/A, not applicable or
482 not stated. Y-axis: Logarithmic representation of the target sizes. Outliers are titled with their
483 individual trial-ID. Data was extracted from the original dataset downloaded from the ICTRP and
484 from the original registration record of each trial.

485

486 **Assessment of redundancies**

487 To identify possible redundancies among all interventional trials we analyzed the different therapeutic
 488 agents being investigated. (Table 7) We identified a total of 261 trials which used a therapeutic agent
 489 other than complementary or alternative medicine and advanced medicinal products. Of those 261
 490 trials 200 were still active and 61 discontinued. Over all 261 trials we identified 94 different drugs.
 491 (Hydroxy)-chloroquine was by far the drug tested most often with 31,8 % trials. After that ritonavir,
 492 lopinavir and interferons were tested most often in decreasing order. (Hydroxy)-chloroquine also had
 493 the highest rate on discontinued trials with 38,6 % out of 83 total trials. This was followed by
 494 remdesivir with 36,4 % and azithromycin with 33,3 %.

495
 496 **Table 7. Assessment of redundancies – Analysis of investigated therapeutic agents across all**
 497 **interventional trials.**

	Active	Discontinued	Total	Discontinued/Total
Interventional trials	490	103	593	17,4%
Therapeutic agents				
(Hydroxy)-Chloroquine	51 (10,4%)	32 (31,1%)	83 (14,0%)	38,6%
Ritonavir	35 (7,1%)	5 (4,9%)	40 (6,7%)	12,5%
Lopinavir	30 (6,1%)	5 (4,9%)	35 (5,9%)	14,3%
Interferone	24 (4,9%)	1 (1,0%)	25 (4,2%)	4,0%
Tocilizumab	11 (2,2%)	4 (3,9%)	15 (2,5%)	26,7%
Favipiravir	12 (2,4%)	0 (0%)	12 (2,0%)	0%
Azithromycin	8 (1,6%)	4 (3,9%)	12 (2,0%)	33,3%
Remdesivir	7 (1,4%)	4 (3,9%)	11 (1,9%)	36,4%
Corticosteroids	7 (1,4%)	3 (2,9%)	10 (1,7%)	30,0%
Arbidol	6 (1,2%)	2 (1,9%)	8 (1,3%)	25,0%
Vitamin C	2 (0,4%)	3 (2,9%)	5 (0,8%)	60,0%
Oseltamivir	5 (1,0%)	0 (0%)	5 (0,8%)	0%
Losartan	4 (0,8%)	1 (1,0%)	5 (0,8%)	20,0%
ACEs/ARBs	2 (0,4%)	2 (1,9%)	4 (0,7%)	50,0%
Ribavirin	4 (0,8%)	0 (0%)	4 (0,7%)	0%

498 All numbers are total counts. Percentages refer to the respective value of the row “Interventional
 499 trials”. Data was extracted from the original database downloaded from the ICTRP and the original
 500 registration record of each trial.

501

502 **Discussion**

503 **Key results and interpretation**

504 **First objective: assessment of spatial and temporal evolution of clinical** 505 **research of COVID-19 across the globe**

506 Our key findings for this objective were: 1) The overall research activity was much higher than in any
507 pandemic, epidemic or health crisis before. 2) China was the country with the most registered trials in
508 total and per confirmed cases, however in terms of trials per population size, the Netherlands and
509 France were leading. Looking at the evolution of the numbers from each country though, it appears
510 that the number of trials per cases and population will align over time. 3) Our results suggest that
511 declarations and warnings from institutions like the WHO did not have that much of an impact on the
512 emergence of clinical research. Rather, clinical research might had been triggered by panic due to
513 rising disease incidence.

514 1) Our initial sampling goal of 1000 registered trials was reached after only approximately 3 months
515 while the current total number of registered trials (accessed 29th of June 2023) in the ICTRP related to
516 COVID-19 was 15834. For other pandemics and epidemics, the total numbers of registered trials were
517 significantly lower, e.g., H1N1 (n=509), Ebola (n=140), SARS (n=4053), MERS (n=21) and even
518 HIV/Aids (n=11764). To put this into perspective, H1N1, Ebola and MERS combined did not have as
519 many registered trials as we found for COVID-19 in the first 3 months.(11)

520 2) The temporal and spatial development of clinical research in the COVID-19 pandemic in general
521 followed the spread of the disease, which was expected. China was the most dominant country with
522 more than two thirds of all trials originating from there and leading on the number of trials per 100
523 cases with 0,806 vs. Japan being second with 0,512 trials per 100 cases. Considering trials per
524 population though, China was not as dominant as the previous numbers might imply with 0,465 trials
525 per 1 million inhabitants vs. Netherlands with 0,8 and France with 0,682. Another trial which
526 examined the characteristics of published scientific articles in the first 3 months of the COVID-19
527 outbreak came to similar results with China having published more than half of the articles with
528 50,5 % and 0,422 articles per 1 million inhabitants.(12) However, in terms of articles per 100 disease

529 cases, our study shows different results. In our study China registered third most trials per cases while
530 China was in the bottom end of articles per cases in the opposed study. The opposed study took the
531 number of confirmed cases from the 2nd of March 2020, before the COVID-19 situation was declared
532 as a pandemic, while our designated date was set one month later on the 1st of April 2020 and after the
533 declaration, which could explain the differences. Thus, in our study, the number of confirmed cases
534 per country was significantly higher, especially in countries other than China due to the vast spread of
535 the disease in March 2020, and thereby the differences in terms of trials per cases are smaller. Our
536 results suggest that the numbers of trials per cases will continue to align over time, and thus China will
537 only be standing out in the first few months of the COVID-19 outbreak.

538 3) Nevertheless, the fact that only 4,9 % of all trials before the pandemic declaration by the WHO
539 originated from outside of China was still surprising, since the outbreak was declared “a public health
540 emergency of international concern” one month prior to being officially declared a pandemic. One
541 would have expected a more robust response at this time.(1) The graphical development of the
542 cumulative cases and trials per date of each region could be an explanation for this. (Fig 3) We see that
543 in all countries except China the number of cases began to increase dramatically only a few days
544 before the declaration, which was then followed by a rapid growth of registered trials. In China on the
545 other hand, the number of cases stagnated around the same time which was then followed by a
546 flattening curve of registered trials. All in all, this raises the question of whether official declarations
547 by the WHO or other institutions are influencing the start of research or whether panic due to the
548 individual case numbers in each country are the main driver for research. Our findings, however,
549 imply the latter.

550

551 **Second objective: assessment of transparency and quality – trial** 552 **registration**

553 Our key findings for this objective were: 1) There is a lack of transparency in trial registration
554 expressed by retrospective registration and registration records not kept up to date with conflicting and
555 invalid information being displayed. 2) The overall quality of trial registration seems to have improved
556 since the introduction of the Trial Registration Data Set, yet there is still crucial information missing.

557 Trial registration is a crucial instrument which aims to ensure transparency, quality and validity of
558 research and therefore prevent publications bias, reproducibility bias, and selective reporting bias. (7,
559 13) Transparency of trial registration was defined as maintaining the trial registration records and
560 updating them in a timely manner, to ensure that every information extracted from these records can
561 be considered as valid and up to date. The quality of trial registration was assessed by screening each
562 registration record for prospective registration and for completeness of the trial registration data set.

563 1) Prospective registration is an important tool to prevent selective reporting and publication bias. By
564 making registration records a public matter before recruiting the first patient, it is very unlikely to alter
565 the data to fit the results since every change to the protocol or record is publicly accessible. (7, 13, 14)
566 This topic is also stated in the declaration of Helsinki with the words “Every research study involving
567 human subjects must be registered in a publicly accessible database before recruitment of the first
568 subject”.(15) The ICMJE therefore requires prospective registration from every clinical trial initiated
569 after July 1, 2005 in order to be considered for publication in any of their member journals.(16).
570 Though, several studies concluded that retrospective registration and thus the possibility of publication
571 and selective reporting bias is still present.(17, 18) One study, which analyzed all trials registered in
572 the ANZCTR from 2006 to 2015, came to the result that the number of prospectively registered trials
573 increased from 42 % in 2006 to 63 % in 2012 and plateaued from thereon.(19) Our study came to
574 similar results with one third of all trials being registered retrospectively. Particularly problematic is
575 the fact that we identified 15 trials which were registered retrospectively after the recruitment was
576 already completed. Although other studies suggest that the number of trials which are being registered
577 retrospectively appear to decrease, there is still a lot of work to do. If retrospective registration exists,
578 selective reporting and publication bias will be a reoccurring problem. Registries and especially
579 journals are in need follow the ICMJE rules more strictly by no longer accepting and publishing
580 studies that were registered retrospectively to overcome this issue.

581 Keeping trial records up to date is another very important aspect of trial registration. To enforce this,
582 all primary and partner registries in the WHO Registry Network signed a form which endeavors to
583 keep registered information up-to-date, some registries even implemented reminder systems to
584 facilitate this by notifying the authors at least every 6 months if there was no update.(20) To our

585 knowledge this is the first study which conducted a follow-up to track the progression of trial
586 registration records over time to evaluate the accuracy and validity of the information being displayed.
587 We discovered that two thirds of the trials haven't been updated accordingly and a quarter of all trials
588 have never been updated after two years since their registration. Particularly unfortunate is the fact that
589 more than half of all trials which already published results were not even labelled as completed. One
590 of the goals of trial registration is that the public and scientific community can consider every
591 information and data displayed as accurate and valid. If this is not ensured for arguably one of the
592 most important and fundamental information in trial registration, i.e., the recruitment status, the whole
593 concept of trial registration is to be questioned.

594 2) The Trial Registration Data Set (TRDS), which was designed by the WHO and is required by the
595 ICMJE, represents another tool to ensure transparency, quality and validity in clinical research and
596 trial registration by providing a minimum set of items each trial record has to display in order to be
597 considered adequate and eligible for publication.(21) To ensure this and to further conquer publication
598 and reproducibility bias, it is crucial that the information of several key items (i.e. interventions,
599 contact information, study type) is informative and complete. Though, our results showed that there
600 were several items with a high rate of missing or insufficient information, e.g., Item 13 (interventions)
601 with 43,9 %, Item 21 (ethics review) with 40,2 % and Item 15 (study type) with 22,4 %. Also, only
602 26/139 (18,7 %) trials displayed Item 13 (summary results) sufficiently and either provided a link or a
603 summarization for already published results. We also detected differences between the registries on
604 which items are missing most often. The ChiCTR for example displayed insufficient information for
605 item 13 (interventions) in 61 % and for item 15 (study type) in 40,9 % of all their records, while
606 ClinicalTrials.gov was missing Item 21 (ethics review) in 97,1 % of their registration records and item
607 7 and 8 (contact for public and scientific queries) in 44,8 %. One study, which took a random sample
608 of 439 records registered between 2008 and 2009 from the ICTRP and assessed those in terms of their
609 contact, intervention and primary outcome information, found that 32,3 % of the trials have not
610 provided sufficient contact information and only 44,2 % provided sufficient information on
611 interventions.(22) Another study conducted by the same authors 4 years later with the same design
612 found that 15,1 % of the trials have not provided sufficient contact information and only 51,9 %

613 provided sufficient information on interventions.(23) In our study only 3,9 % trials were completely
614 missing the contact information of which all were registered on ClinicalTrials.gov. The differences
615 regarding the contact information can be explained with the fact that in our study ClinicalTrials.gov is
616 underrepresented with 35,1 % of all trials being registered on this register compared to 85,9 %
617 respectively 57,5 % in their studies. Results from another study in 2009 which assessed the whole data
618 set (at that time only 20 items) showed a much higher rate of missing information for nearly every
619 item. (24) Since these studies depict rather the early years after trial registration was implemented, our
620 findings also suggest that there was an overall improvement in registration quality over time, yet some
621 key items like interventions have been and still are missing critical information. These suggestions
622 meet the results from two recent studies which assessed the quality of trial records investigating
623 Traditional Chinese Medicine. The authors concluded that especially the complex items like
624 interventions, study design and primary outcomes were missing crucial information. (25, 26)
625 Although, the implementation of trial registration and therefore compliance with the TRDS was
626 advocated over 17 years ago, there is evidently still a huge lack of quality and transparency. To
627 conquer publication bias, selective reporting bias and reproducibility bias, institutions like the WHO
628 and the ICMJE, must work more closely with the registers, journals, and researchers to overcome
629 these issues. As a possible solution for the differences between registers, lack of quality in trial
630 registration and to ensure that the information is displayed equally, we suggest a unified item mask
631 which each register must implement to be considered as a partner for the WHO Registry Network and
632 be eligible for publication. This, however, must be enforced by the WHO and the ICMJE, as there is
633 no need for registers to change if their trials are still being published.

634

635 **Third objective: assessment of research waste and redundancies**

636 Our key findings for this objective are: 1) The early stages of clinical research about COVID-19
637 showed clear signs of research waste. Furthermore, research waste appears to be a reoccurring
638 problem in the scientific world. 2) “Hype train phenomenon” in early stages of research assumingly
639 due to a lack of dedicated supervising institutions and coordination which leads to unnecessary
640 redundancies and ultimately to more research waste.

641 Research waste and redundancies in clinical research are significant problems that can have serious
642 implications for the scientific community, as well as for the patients who participate in clinical trials.
643 Research waste refers to the unnecessary use of resources including time, money, and other valuable
644 resources. Research waste will therefore be measured by the rate of discontinuation and the quality of
645 study design. Redundancies, on the other hand, occur when multiple studies are conducted on the same
646 or similar topics, resulting in duplication of efforts and resources. To assess this issue, we screened all
647 drug trials for their therapeutic agents to depict potential redundancies which would also lead to more
648 research waste.

649 1) Discontinuation displays one source for wasting money, time, and other valuable resources. (27-29)
650 Nearly 2 years after the last trial of our study was registered, we identified 17,3 % discontinued
651 interventional trials. The most common reason for discontinuation was difficulties with enrolment of
652 patients with 29,1 % trials. Discontinuation rates ranging from as low as 11 % and up to 43 % had
653 been displayed in several other studies. Similar to our findings, the most common reason for
654 discontinuation in all of those trials was difficulties with enrolment.(27, 28, 30-34) However, a
655 systematic review from 2016 suggested that most reasons for recruitment failure could be anticipated
656 in the planning phase of a trial and thus are preventable. The authors also provided a checklist to
657 ensure that weak spots in study designs are being identified.(35) Since transparency is important to
658 detect errors in the planning of studies and to prevent them in the future, it is even more problematic if
659 no reason for discontinuation is given. Unfortunately, 39,8 % had not stated any reason for
660 discontinuation. Even in discontinued trials, transparency is important to detect errors in the planning
661 of trials and prevent those mistakes in the future by learning from one another.

662 Another important aspect to avoid research waste is an appropriate and robust study design. Although,
663 more than two thirds of all interventional trials are designed as RCTs, which are mostly ranked on top
664 of the evidence levels and hailed as the “gold-standard” of evidence-based-medicine, almost one third
665 of trials used other designs, often without any control, which is ranked on the bottom of the evidence
666 pyramid.(36) Further, even the RCTs have flaws in their design as nearly half of them were not
667 masked which can lead to several bias such as selection bias, which was supposed to be eliminated by

668 the randomization itself.(37) We speculate that panic and the willingness to help may have driven
669 these “short-cuts” in robustness.

670 2) To further avoid research waste, it is also important to create awareness for redundancies in clinical
671 research. Trial registration was intended as a tool to diminish this by making planned and ongoing
672 research available for the public and scientific world.

673 (Hydroxy)-chloroquine (HCQ/QC), as the most prominent example, gained huge popularity in the
674 early months of COVID-19. However, the timeline of HCQ/QC showed contradicting information
675 about the pros and cons of its therapeutic use against COVID-19 which was also influenced by the
676 media and even leading politicians in effected countries.(38) The therapeutic use was halted when the
677 US-FDA revoked its emergency authorization on June 15, 2020.(39) Early reviews from 2020
678 supported this by indicating weak and conflicting evidence about the efficacy and safety of HCQ/CQ.
679 (40-43) Throughout this evolution, there was always an urgent call for better designed and properly
680 powered trials to gain unequivocal data safety and efficacy for HCQ/CQ usage in COVID-19. (41, 44)
681 Though, our results show that 14 % of all interventional trials investigated the usage HCQ/CQ with
682 more than a third (38,6 %) of those trials being discontinued before completion. This is not only an
683 example for research waste and redundancies but also raises the question on whether numerous trials
684 assessing the same topic operationally fragmented in isolated silo-structures fulfils the purpose of
685 gaining more evidence. The given tools (e.g., trial registration and the registers itself) must be used
686 more thoroughly to detect similar trials and encourage collaboration instead of conducting own trials
687 one after the other without any coordination. This could not only help with the power of trials but
688 could also lower the discontinuation rates by preventing recruitment failure through multicentric
689 designs and thus also prevents unnecessary exposure to clinical trials for patients.

690

691 **Limitations**

692 The limitations of this study are the following:

693 1) Since the registered trials are updated on a regular weekly basis the data at the point of download
694 from the WHO ICTRP search portal can be considered as up to date as of the 22nd of April, meaning
695 all trials registered to this date were considered for inclusion in this study. Nevertheless, we cannot

696 rule out with complete certainty that no additional trials were added afterwards which could lead to a
697 different number of included trials if the dataset was downloaded on another date. Also, we expect the
698 data set to be different if downloaded now, since the trial registration protocols can be updated and
699 changed and therefore the information displayed in the data set by the WHO will also be changed.

700 2) We only used the keyword “COVID-19” as a search criterion which could have biased our search
701 outcome.

702 3) Since our objective was to observe and analyze the first surge of clinical research and our goal of
703 1000 registered trials was already exceeded on the 1st of April 2020, we only cover a small period. Our
704 findings therefore only describe the early stages of this pandemic, i.e., the initial “chaos phase” and are
705 definitively not generalizable to the entire pandemic.

706 4) As this study only evaluates the quality and validity of the registration records, we do not presume
707 to make any statement about the ultimate quality of the trials itself. Further studies must assess
708 whether the quality deficiencies we have identified in the records are carried through to publication.

709 5) Including a larger number of clinical trials would have allowed a better inside but we deliberately
710 chose to only assess the early stages of such a situation. It would be interesting to investigate if the
711 results of this analysis changed along the pandemic.

712

713 **Conclusion**

714 To our knowledge, this is the first study which examined the quality of trial registration in the early
715 “chaos phase” of the COVID-19 pandemic and the first study which conducted a follow-up to assess
716 the development of the recruitment status of registration records. The temporal and spatial evolution of
717 clinical research turned out as expected. China, being the country the virus originated from, was the
718 first country to start clinical research and was overall the country with the most registered trials in the
719 first months of the pandemic. The spread of the disease was also accompanied by emerging trials from
720 other countries, and it appears that official pandemic declarations from institutions like the WHO have
721 less impact on the uprising of research than the number of cases in each country. While the
722 information of trial records is easily available and accessible for everybody, we detected a huge lack of
723 quality and validity, which is not due to the pandemic situation but rather a general problem. With the

724 data we found and the experience we gathered while examining the trial records, we highly doubt the
725 meaningfulness and benefit of trial registration in its current form, especially for rapidly evolving
726 situations across global geographies and language zones. If the information is incomplete, not up-to-
727 date and registered retrospectively, the usefulness is not given. Registries will therefore only be used
728 for mandatory registration and thus are deprived from other important functions: 1) facilitating
729 recruitment by creating awareness for researchers and possible participants about recruiting trials 2)
730 enabling and improving collaboration between researchers 3) identifying gaps in clinical research 4)
731 avoiding redundancies by identifying similar trials 5) reducing research waste by identifying potential
732 problems in study design. Especially in the “scientific chaos phase” of an emerging pandemic like
733 COVID-19, these functions can be of tremendous help by being an organizer of chaos and therefore
734 reducing information overload and research waste. Advocating and emphasizing these functions can
735 furthermore help in the early stages of future pandemics and epidemics by preventing chaos and panic
736 before it even emerges. An important mission of the WHO is to break the “panic-then-forget” cycle in
737 future health crisis.(45) The scientific response proved to be intact. Many colleagues all over world
738 fought the pandemic with dedication, bravery, and sacrifices, but as Dr. Mike Ryan from the WHO
739 stated: “Preparation is the most active act in public health, not response. Preparation is response, and
740 we make a false separation between these concepts.”(45, 46) Scientific communication and
741 coordination tools such as clinical trials registry tools - if kept current and accurate - are valuable
742 instruments to strengthen societal resiliency in global, medical disaster situations. Appropriate disaster
743 preparation implies that these systems be optimized - taking our findings and suggestions for
744 improvement into account - before the next disaster strikes.(47, 48)

745 We believe that the WHO in cooperation with the ICMJE can have the most impact on improving
746 quality and usefulness of trial registration as they define the requirements for registration and
747 publication.

748

749 **Acknowledgments**

750 This research article is part of Till Adamis doctoral thesis.

751

752 **References:**

753

- 754 1. World Health Organization. WHO Director-General's opening remarks at the media
755 briefing on COVID-19 - 11 March 2020: WHO; [cited 2023 31 March]. Available from:
756 <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>.
757
- 758 2. World Health Organization. Statement on the second meeting of the International
759 Health Regulations (2005) Emergency Committee regarding the outbreak of novel
760 coronavirus (2019-nCoV): WHO; [cited 2023 16 March]. Available from:
761 [https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)).
762
763
- 764 3. World Health Organization. ICTRP Registered Trials, Keyword „COVID-19“: WHO;
765 [cited 2023 29 June]. Available from: <https://trialsearch.who.int>.
- 766 4. Ries M. Global key concepts of civil-military cooperation for disaster management in
767 the COVID-19 pandemic-A qualitative phenomenological scoping review. *Front Public*
768 *Health*. 2022;10:975667.
- 769 5. Baker MS. Creating Order from Chaos: Part I: Triage, Initial Care, and Tactical
770 Considerations in Mass Casualty and Disaster Response. *Military Medicine*.
771 2007;172(3):232-6.
- 772 6. Schulze C, Welker A, Kühn A, Schwertz R, Otto B, Moraldo L, et al. Public Health
773 Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency
774 Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19
775 Pandemic. *Vaccines*. 2021;9(8):887.
- 776 7. World Health Organization. Trial registration: WHO; [cited 2023 15 March].
777 Available from: <https://www.who.int/clinical-trials-registry-platform/network/trial-registration>.
778
- 779 8. World Health Organization. WHO Registry Criteria: WHO; [cited 2023 16 March].
780 Available from: <https://www.who.int/clinical-trials-registry-platform/network/registry-criteria>.
781
- 782 9. World Health Organization. WHO Trial Registration Data Set: WHO; [cited 2023 16
783 March]. Available from: <https://www.who.int/clinical-trials-registry-platform/network/who-data-set>.
784
- 785 10. World Health Organization. ICTRP Registry Network: WHO; [cited 2023 17 March].
786 Available from: <https://www.who.int/ictip/network/en/>.
- 787 11. World Health Organization. ICTRP Registered Trials, Keywords „H1N1“ OR „Ebola“
788 OR „HIV“ OR „AIDS“ OR „MERS“ OR „SARS“: WHO; [cited 2023 07 March]. Available
789 from: <https://trialsearch.who.int>.
- 790 12. Di Girolamo N, Meursing Reynders R. Characteristics of scientific articles on
791 COVID-19 published during the initial 3 months of the pandemic. *Scientometrics*.
792 2020;125(1):795-812.
- 793 13. Abaid LN, Grimes DA, Schulz KF. Reducing Publication Bias Through Trial
794 Registration. *Obstetrics & Gynecology*. 2007;109(6):1434-7.
- 795 14. Harvey LA. Trial registration: a pre-requisite for publication and an ethical
796 responsibility. *Spinal Cord*. 2017;55(4):329-30.
- 797 15. World Medical Association. WMA DECLARATION OF HELSINKI – ETHICAL
798 PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS: WMA;

- 799 [cited 2023 16 March]. Available from: [https://www.wma.net/policies-post/wma-declaration-](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/)
800 [of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/).
- 801 16. International Committee of Medical Journal Editors. Clinical Trials Registration:
802 ICMJE; [cited 2023 28 March 2023]. Available from: [https://www.icmje.org/about-](https://www.icmje.org/about-icmje/faqs/clinical-trials-registration/)
803 [icmje/faqs/clinical-trials-registration/](https://www.icmje.org/about-icmje/faqs/clinical-trials-registration/).
- 804 17. Dal-Ré R, Ross JS, Marušić A. Compliance with prospective trial registration
805 guidance remained low in high-impact journals and has implications for primary end point
806 reporting. *Journal of Clinical Epidemiology*. 2016;75:100-7.
- 807 18. Gopal AD, Wallach JD, Aminawung JA, Gonsalves G, Dal-Ré R, Miller JE, et al.
808 Adherence to the International Committee of Medical Journal Editors' (ICMJE) prospective
809 registration policy and implications for outcome integrity: a cross-sectional analysis of trials
810 published in high-impact specialty society journals. *Trials*. 2018;19(1):448.
- 811 19. Hunter KE, Seidler AL, Askie LM. Prospective registration trends, reasons for
812 retrospective registration and mechanisms to increase prospective registration compliance:
813 descriptive analysis and survey. *BMJ Open*. 2018;8(3):e019983.
- 814 20. World Health Organization. Primary registries in the WHO registry network: WHO;
815 [cited 2023 16 March]. Available from: [https://www.who.int/clinical-trials-registry-](https://www.who.int/clinical-trials-registry-platform/network/primary-registries)
816 [platform/network/primary-registries](https://www.who.int/clinical-trials-registry-platform/network/primary-registries).
- 817 21. International Committee of Medical Journal Editors. Clinical Trials: ICMJE; 2023
818 [cited 2023 29 March]. Available from:
819 [https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-](https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html)
820 [registration.html](https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html).
- 821 22. Viergever RF, Ghersi D. The Quality of Registration of Clinical Trials. *PLOS ONE*.
822 2011;6(2):e14701.
- 823 23. Viergever RF, Karam G, Reis A, Ghersi D. The Quality of Registration of Clinical
824 Trials: Still a Problem. *PLOS ONE*. 2014;9(1):e84727.
- 825 24. Moja LP, Moschetti I, Nurbhai M, Compagnoni A, Liberati A, Grimshaw JM, et al.
826 Compliance of clinical trial registries with the World Health Organization minimum data set:
827 a survey. *Trials*. 2009;10(1):56.
- 828 25. Kuang Z, Li X, Cai J, Chen Y, Qiu X, Ni X, et al. Calling for improved quality in the
829 registration of traditional Chinese medicine during the public health emergency: a survey of
830 trial registries for COVID-19, H1N1, and SARS. *Trials*. 2021;22(1):188.
- 831 26. Liu X, Li Y, Yu X, Feng J, Zhong X, Yang X, et al. Assessment of registration quality
832 of trials sponsored by China. *Journal of Evidence-Based Medicine*. 2009;2(1):8-18.
- 833 27. Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A.
834 Discontinuation and non-publication of surgical randomised controlled trials: observational
835 study. *BMJ : British Medical Journal*. 2014;349:g6870.
- 836 28. Kasenda B, von Elm E, You J, Blümle A, Tomonaga Y, Saccilotto R, et al.
837 Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. *JAMA*.
838 2014;311(10):1045-52.
- 839 29. Yilmaz T, Jutten RJ, Santos CY, Hernandez KA, Snyder PJ. Discontinuation and
840 nonpublication of interventional clinical trials conducted in patients with mild cognitive
841 impairment and Alzheimer's disease. *Alzheimer's & Dementia: Translational Research &*
842 *Clinical Interventions*. 2018;4(1):161-4.
- 843 30. Khan MS, Shahid I, Asad N, Greene SJ, Khan SU, Doukky R, et al. Discontinuation
844 and non-publication of heart failure randomized controlled trials: a call to publish all trial
845 results. *ESC Heart Fail*. 2021;8(1):16-25.
- 846 31. Rosenthal R, Kasenda B, Dell-Kuster S, von Elm E, You J, Blümle A, et al.
847 Completion and Publication Rates of Randomized Controlled Trials in Surgery: An Empirical
848 Study. *Annals of Surgery*. 2015;262(1):68-73.


- 849 32. Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, et al. Preliminary
850 evaluation of factors associated with premature trial closure and feasibility of accrual
851 benchmarks in phase III oncology trials. *Clin Trials*. 2010;7(4):312-21.
- 852 33. Tiefenbach J, Park JJ, Demetriades AK. Trial Discontinuation and Publication
853 Outcome:Resource Wastage in Low Back Pain Research. *Spine*.
854 9900:10.1097/BRS.0000000000004524.
- 855 34. Traxler BD, Rucker BM, Greenough MC, Sajjadi NB, Hartwell M. Influence of the
856 COVID-19 Pandemic on Clinical Trial Discontinuation in Anesthesiology: Cross-sectional
857 Analysis. *JMIR Perioper Med*. 2022;5(1):e34936.
- 858 35. Briel M, Olu KK, von Elm E, Kasenda B, Alturki R, Agarwal A, et al. A systematic
859 review of discontinued trials suggested that most reasons for recruitment failure were
860 preventable. *Journal of Clinical Epidemiology*. 2016;80:8-15.
- 861 36. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-
862 based medicine. *Plast Reconstr Surg*. 2011;128(1):305-10.
- 863 37. Viera AJ, Bangdiwala SI. Eliminating bias in randomized controlled trials: importance
864 of allocation concealment and masking. *Fam Med*. 2007;39(2):132-7.
- 865 38. Ries M. The COVID-19 Infodemic: Mechanism, Impact, and Counter-
866 Measures—A Review of Reviews. *Sustainability*. 2022;14(5):2605.
- 867 39. Manivannan E, Karthikeyan C, Moorthy NSHN, Chaturvedi SC. The Rise and Fall of
868 Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19. *Frontiers in*
869 *Pharmacology*. 2021;12.
- 870 40. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM.
871 Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19. *Annals of*
872 *Internal Medicine*. 2020;173(4):287-96.
- 873 41. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on
874 the efficacy and safety of chloroquine for the treatment of COVID-19. *Journal of Critical*
875 *Care*. 2020;57:279-83.
- 876 42. Altulea D, Maassen S, Baranov MV, van den Bogaart G. What makes
877 (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. *Journal of*
878 *Molecular Cell Biology*. 2021;13(3):175-84.
- 879 43. Sturrock BR, Chevassut TJ. Chloroquine and COVID-19 – a potential game changer?
880 *Clinical Medicine*. 2020;20(3):278-81.
- 881 44. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. *BMJ*.
882 2020;369:m1432.
- 883 45. World Health O. Sustainable preparedness for health security and resilience: adopting
884 a whole-of-society approach and breaking the “panic-then-forget” cycle: meeting report: side
885 event, 75th Session of the United Nations General Assembly, 1 October 2020. Geneva: World
886 Health Organization; 2020 2020.
- 887 46. World Health Organization. Health and Care Worker Deaths during COVID-19:
888 WHO; [cited 2023 09 July]. Available from: [https://www.who.int/news/item/20-10-2021-
889 health-and-care-worker-deaths-during-covid-19](https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-covid-19).
- 890 47. Brennenstuhl H, Will M, Ries E, Mechler K, Garbade S, Ries M. Patterns of extreme
891 temperature-related catastrophic events in Europe including the Russian Federation: a cross-
892 sectional analysis of the Emergency Events Database. *BMJ Open*. 2021;11(6):e046359.
- 893 48. Ries M, Zielonka M, Ries N, Breil T, Garbade S, Mechler K. Disasters in Germany
894 and France: An Analysis of the Emergency Events Database From a Pediatric Perspective.
895 *Disaster Med Public Health Prep*. 2019;13(5-6):958-65.

898 **Supporting information**

899 **S1 Supporting information. STROBE-Statement checklist**

900 **S2 Supporting information. Trial Registration Data Set items**

PRISMA-flow chart of trial selection



medRxiv preprint doi: <https://doi.org/10.1101/2023.07.14.23292667>; this version posted July 18, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Fig1

Cumulative Trials China vs. Rest of the World




Fig2

Cumulative Cases vs. Trials China




Fig3

Cumulative Cases vs. Trials US




Fig4

Cumulative Cases vs. Trials France




Fig5

Cumulative Cases vs. Trials Iran




Fig6

Cumulative Cases vs. Trials Italy




Fig7

Cumulative Cases vs. Trials Germany




Fig8

Cumulative Cases vs. Trials UK




Fig9

Cumulative Cases vs. Trials Netherlands




Fig10

Cumulative Cases vs. Trials Spain




Fig11

Cumulative Cases vs. Trials Canada




Fig12

Cumulative Cases vs. Trials Japan




Fig13




Fig14




Fig15